Compare
Thermo Fisher Scientific Inc. vs Rockwell Automation, Inc
| Latest fiscal year | Thermo Fisher Scientific Inc. TMO | Rockwell Automation, Inc ROK |
|---|---|---|
| Year ended | 2025-12-31 | 2025-09-30 |
| Revenue | $44.56B | $8.34B |
| Revenue growth (YoY) | +3.9% | +0.9% |
| Gross margin | n/a | 48.1% |
| Operating margin | 17.4% | 20.4% |
| Net margin | 15.0% | 10.4% |
| Net income | $6.70B | $869.00M |
| EPS (Diluted) | $17.74 | $7.67 |
| Operating cash flow | $7.82B | $1.54B |
| Free cash flow | $6.29B | $1.36B |
| Cash & equivalents | $9.85B | $468.00M |
| Total assets | $110.34B | $11.22B |
| Total liabilities | n/a | n/a |
| Shareholders' equity | $53.41B | $3.65B |
| Return on year-end equity | 12.6% | 23.8% |
| Shares outstanding | n/a | 112.40M |
Revenue, most recent five fiscal years
| Fiscal year | Thermo Fisher Scientific Inc. | Rockwell Automation, Inc |
|---|---|---|
| Latest | $44.56B Ended 2025-12-31 | $8.34B Ended 2025-09-30 |
| 1 year earlier | $42.88B Ended 2024-12-31 | $8.26B Ended 2024-09-30 |
| 2 years earlier | $42.86B Ended 2023-12-31 | $9.06B Ended 2023-09-30 |
| 3 years earlier | $44.91B Ended 2022-12-31 | $7.76B Ended 2022-09-30 |
| 4 years earlier | $39.21B Ended 2021-12-31 | $7.00B Ended 2021-09-30 |